Nifty Pharma 22011.7 (-3.33)
Nifty Smallcap 100 17668.2 (-1.66)
Nifty 50 24565.35 (-0.82)
Nifty IT 34649.6 (-1.85)
Nifty Midcap 100 56637.15 (-1.33)
SENSEX 80599.91 (-0.72)
Nifty Next 50 66192.8 (-1.35)
Nifty Bank 55617.6 (-0.62)
NIKKEI 225 40799.6 (-0.66)
HANG SENG 24507.81 (-1.07)
S&P 6275.25 (-1.74)
23-Jul-2025
Net up 30% largely on higher sales and higher OI
' Consolidated net sales (including other operating income) of KEI Industries for the quarter ended Jun 2025 has increased 25.44% to Rs 2590.32 crore. Operating profit margin has declined from 10.61% to 9.96%, leading to 17.77% rise in operating profit to Rs 258.01 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 76.48% to 77.06%. Employee cost increased from 3.14% to 3.17%. Other expenses fell from 10.93% to 10.19%. Expenses from contract fell from 1.66% to 0.63%. Other income rose 197.15% to Rs 39.61 crore. PBIDT rose 28.06% to Rs 297.62 crore. Provision for interest rose 2.40% to Rs 14.5 crore. PBDT rose 29.72% to Rs 283.12 crore. Provision for depreciation rose 28.32% to Rs 19.89 crore. Profit before tax grew 29.83% to Rs 263.23 crore. Share of profit/loss were nil in both the periods. P...
(01-Aug-2025)
Sales up 2%, net down 3%
Net up 34% on higher sales
Sales up 23%, net down 9% as OPM down by 410 bps
AUM rises 24%, disbursements up 15% for Q1FY2026
Results-Analysis (23-Jul-2025)
Analyst Meet / AGM-Conference Call (23-Jul-2025)
Expect to close FY26 with a revenue growth of 18-19% with EBITDA margin close to 11%.
Analyst Meet / AGM-Conference Call (08-May-2025)
Expect over 20% growth in revenue in FY27 onwards
Results-Analysis (07-May-2025)
Net up 34% on higher sales and higher OI